Conflict of interest: L. G. H. has received research institutional grant funding from MedImmune, Novartis UK, Genentech, F. Hoffman-La Roche Ltd, AstraZeneca, and GlaxoSmithKline and has taken part on advisory boards and given lectures at meetings supported by GlaxoSmithKline, Merck Sharpe & Dohme Limited, Nycomed, Novartis AG, F. Hoffman-La Roche Ltd, Boehringer-Ingelheim GmbH, Teva Pharmaceuticals Industries Ltd, Chiesi, and AstraZeneca. He has received support funding to attend international respiratory meetings (AstraZeneca, Chiesi, Novartis AG, Boehringer-Ingelheim GmbH, and GlaxoSmithKline) and has taken part in asthma clinical trials (GlaxoSmithKline, Genentech, Synairgen, and F. Hoffman-La Roche Ltd) for which his institution was remunerated. C. E. B. has received consultancy and grant funding from AstraZeneca/MedImmune, Roche/Genentech, Novartis AG, GlaxoSmithKline, Chiesi, Almirall, and Boehringer-Ingelheim GmbH. In the past 5 years, R. N. has received lecture fees from the following pharmaceutical companies: AstraZeneca, Novartis AG, GlaxoSmithKline, Boston Scientific, and Boehringer-Ingelheim GmbH. He has participated on advisory boards and has received income for this work over 5 years from the following companies: Vectura, Boston Scientific, GlaxoSmithKline, and Novartis AG. A. H. M. has received educational grants, travel sponsorship, and fees for lecturing and sitting in advisory board meetings for GlaxoSmithKline, AstraZeneca, Novartis AG, Boehringer-Ingelheim GmbH, NAPP, F. Hoffman-La Roche Ltd, and others. R. C. has received an unrestricted educational grant from Novartis AG to improve local asthma services and sponsorship to attend conferences from GlaxoSmithKline, Novartis AG, Teva Pharmaceuticals Industries Ltd, and Boehringer-Ingelheim GmbH; has participated in advisory board meeting (Novartis AG); and has taken part in asthma clinical trials (F. Hoffman-La Roche Ltd, GlaxoSmithKline, AstraZeneca, Janssen Pharmaceutica, Novartis AG, and Genentech) for which her institution was remunerated. C. E. B. has received speaker’s fees and consultancy fees from Novartis AG, GlaxoSmithKline, and AstraZeneca which go to her research fund (ie, not personal) and financial support to attend international conferences from GlaxoSmithKline and Novartis AG. In the past 12 months, A. N. M.-G. has attended advisory boards for F. Hoffman-La Roche Ltd, Johnson & Johnson, Amgen, and Boehringer-Ingelheim GmbH. He has received lecture fees from Novartis AG, NAPP, GlaxoSmithKline, Boehringer-Ingelheim GmbH, and Chiesi. He has attended international conferences with Boehringer-Ingelheim GmbH and Novartis AG. He is currently participating in clinical studies funded by F. Hoffman-La Roche Ltd, Boehringer-Ingelheim GmbH, and GlaxoSmithKline. None declared (D. G.).